Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 137,931	$ 108,095	$ 85,543
Cost of revenues:
Total cost of revenues	72,311	44,623	36,450
Gross profit	65,620	63,472	49,093
Operating expenses:
Research and development	90,904	64,695	39,404
Sales and marketing	22,150	17,795	21,364
General and administrative	64,009	41,898	27,040
Total operating expenses	177,063	124,388	87,808
Loss from operations	(111,443)	(60,916)	(38,715)
Other income:
(Loss) gain on equity investments	(1,781)	4,108	943
Change in fair value	11,359	28,263	9,922
Interest income	1,057	2,253	1,878
Total other income	10,635	34,624	12,743
Loss before income taxes	(100,808)	(26,292)	(25,972)
Income tax expense (benefit)	411	345	(291)
Net loss	(101,219)	(26,637)	(25,681)
Net loss attributable to noncontrolling interest	(826)	(2,174)	(1,110)
Net loss attributable to Schrödinger common and limited common stockholders	$ (100,393)	$ (24,463)	$ (24,571)
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:	$ (1.42)	$ (0.41)	$ (4.09)
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:	70,594,950	60,024,658	6,004,500
Software Products and Services
Revenues:
Total revenues	$ 113,236	$ 92,530	$ 66,735
Cost of revenues:
Total cost of revenues	26,495	18,003	13,646
Drug Discovery
Revenues:
Total revenues	24,695	15,565	18,808
Cost of revenues:
Total cost of revenues	$ 45,816	$ 26,620	$ 22,804